164 related articles for article (PubMed ID: 1382831)
1. An immunohistochemical study of epithelial membrane antigen, cytokeratin, and vimentin in papillary thyroid carcinoma. Recognition of lethal and favorable prognostic types.
Yamamoto Y; Izumi K; Otsuka H
Cancer; 1992 Nov; 70(9):2326-33. PubMed ID: 1382831
[TBL] [Abstract][Full Text] [Related]
2. An immunohistochemical study of epithelial membrane antigen, cytokeratin, and vimentin in papillary thyroid carcinoma: recognition of lethal and favorable prognostic types.
Triviño López A; González IC
Cancer; 1993 Oct; 72(7):2286-7. PubMed ID: 7690684
[No Abstract] [Full Text] [Related]
3. High-molecular-weight cytokeratin and cytokeratin-19 in the diagnosis of thyroid tumors.
Raphael SJ; McKeown-Eyssen G; Asa SL
Mod Pathol; 1994 Apr; 7(3):295-300. PubMed ID: 7520169
[TBL] [Abstract][Full Text] [Related]
4. Alcian blue and epithelial membrane antigen are useful markers in differentiating benign from malignant papillae in thyroid lesions.
Damiani S; Fratamico F; Lapertosa G; Dina R; Eusebi V
Virchows Arch A Pathol Anat Histopathol; 1991; 419(2):131-5. PubMed ID: 1871955
[TBL] [Abstract][Full Text] [Related]
5. Anaplastic carcinoma of the thyroid. A clinicopathologic study of 121 cases.
Venkatesh YS; Ordonez NG; Schultz PN; Hickey RC; Goepfert H; Samaan NA
Cancer; 1990 Jul; 66(2):321-30. PubMed ID: 1695118
[TBL] [Abstract][Full Text] [Related]
6. Tall cell variant of papillary thyroid carcinoma: a reassessment and immunohistochemical study with comparison to the usual type of papillary carcinoma of the thyroid.
Ostrowski ML; Merino MJ
Am J Surg Pathol; 1996 Aug; 20(8):964-74. PubMed ID: 8712296
[TBL] [Abstract][Full Text] [Related]
7. Epithelial markers in malignant melanoma. A study of primary lesions and their metastases.
Ben-Izhak O; Stark P; Levy R; Bergman R; Lichtig C
Am J Dermatopathol; 1994 Jun; 16(3):241-6. PubMed ID: 7524376
[TBL] [Abstract][Full Text] [Related]
8. Loss of cellular polarity/cohesiveness in the invasive front of papillary thyroid carcinoma, a novel predictor for lymph node metastasis; possible morphological indicator of epithelial mesenchymal transition.
Liu Z; Kakudo K; Bai Y; Li Y; Ozaki T; Miyauchi A; Taniguchi E; Mori I
J Clin Pathol; 2011 Apr; 64(4):325-9. PubMed ID: 21296795
[TBL] [Abstract][Full Text] [Related]
9. Overall Survival of Papillary Thyroid Carcinoma Patients: A Single-Institution Long-Term Follow-Up of 5897 Patients.
Ito Y; Miyauchi A; Kihara M; Fukushima M; Higashiyama T; Miya A
World J Surg; 2018 Mar; 42(3):615-622. PubMed ID: 29349484
[TBL] [Abstract][Full Text] [Related]
10. Accuracy of World Health Organisation-grade parameters (necrosis and mitotic activity) and foci of vascular invasion in predicting prognosis of papillary thyroid carcinoma. A case-control validation study.
Ragazzi M; Besutti G; Mancuso P; Rossi PG; Ciarrocchi A; Donati B; Manzotti G; Giordano D; Frasoldati A; Chiaruccci F; de de Biase D; Coluccelli S; Maloberti T; De Leo A; Piana S; Tallini G
Histopathology; 2024 Jul; 85(1):62-74. PubMed ID: 38477417
[TBL] [Abstract][Full Text] [Related]
11. Ovarian small cell carcinoma. Histogenetic considerations based on immunohistochemical and other findings.
Aguirre P; Thor AD; Scully RE
Am J Clin Pathol; 1989 Aug; 92(2):140-9. PubMed ID: 2474244
[TBL] [Abstract][Full Text] [Related]
12. Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants.
Chowdhury S; Veyhl J; Jessa F; Polyakova O; Alenzi A; MacMillan C; Ralhan R; Walfish PG
Oncotarget; 2016 May; 7(22):32318-28. PubMed ID: 27086918
[TBL] [Abstract][Full Text] [Related]
13. Papillary thyroid carcinoma with distant metastases: survival predictors and the importance of local control.
Sugitani I; Fujimoto Y; Yamamoto N
Surgery; 2008 Jan; 143(1):35-42. PubMed ID: 18154931
[TBL] [Abstract][Full Text] [Related]
14. Vascular invasion is an independent prognostic factor for distant recurrence-free survival in papillary thyroid carcinoma: a matched-case comparative study.
Cao J; Hu JL; Chen C; Wang QL; Fang XH; Zhang Y; Ge MH
J Clin Pathol; 2016 Oct; 69(10):872-7. PubMed ID: 27010434
[TBL] [Abstract][Full Text] [Related]
15. Papillary thyroid carcinoma: factors influencing recurrence and survival.
Toniato A; Boschin I; Casara D; Mazzarotto R; Rubello D; Pelizzo M
Ann Surg Oncol; 2008 May; 15(5):1518-22. PubMed ID: 18324441
[TBL] [Abstract][Full Text] [Related]
16. Adrenal cortical adenoma and adrenal metastasis of renal cell carcinoma: immunohistochemical and DNA ploidy analysis.
Kumar D; Kumar S
Mod Pathol; 1993 Jan; 6(1):36-41. PubMed ID: 7678935
[TBL] [Abstract][Full Text] [Related]
17. Alpha-1-antichymotrypsin immunoreactivity in papillary carcinoma of the thyroid gland.
Lai ML; Rizzo N; Liguori C; Zucca G; Faa G
Histopathology; 1998 Oct; 33(4):332-6. PubMed ID: 9822922
[TBL] [Abstract][Full Text] [Related]
18. Tall cell variant of papillary thyroid carcinoma: a population-based study in Iceland.
Axelsson TA; Hrafnkelsson J; Olafsdottir EJ; Jonasson JG
Thyroid; 2015 Feb; 25(2):216-20. PubMed ID: 25322334
[TBL] [Abstract][Full Text] [Related]
19. [Meningiomas: immunohistochemical analysis of 26 cases].
Pérez-Guiones Bacete M; Cerda-Nicolás M; Piquer J; Barcia-Mariño C
Arch Neurobiol (Madr); 1992; 55(2):43-9. PubMed ID: 1377465
[TBL] [Abstract][Full Text] [Related]
20. Immunoreactivity for cytokeratin and epithelial membrane antigen in leiomyosarcoma.
Miettinen M
Arch Pathol Lab Med; 1988 Jun; 112(6):637-40. PubMed ID: 2454091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
